Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416565 | 0.86 | KMT2A (0.59) | KDM4ESMN1; SMN2RECQLKMT2AALDH1A1 | |
| SCHEMBL29955891 | 0.83 | KDM4E (0.51) | KDM4ESMN1; SMN2RECQLKMT2AALDH1A1 | |
| SCHEMBL3417817 | 0.83 | MAPK1 (0.59) | KDM4ESMN1; SMN2RECQLKMT2AALDH1A1 | |
| SCHEMBL3411214 | 0.83 | MAPK1 (0.59) | KDM4ESMN1; SMN2RECQLKMT2AALDH1A1 | |
| SCHEMBL3418174 | 0.83 | MAPK1 (0.59) | KDM4ESMN1; SMN2RECQLKMT2AALDH1A1 | |
| SCHEMBL2411241 | 0.82 | SMN1; SMN2 (0.61) | KDM4ESMN1; SMN2RECQLKMT2AALDH1A1 | |
| SCHEMBL14485052 | 0.78 | SMN1; SMN2 (0.71) | KDM4ESMN1; SMN2RECQLKMT2AALDH1A1 | |
| SCHEMBL2192046 | 0.77 | KDM4E (0.54) | KDM4ESMN1; SMN2RECQLKMT2AALDH1A1 | |
| SCHEMBL2192047 | 0.77 | KDM4E (0.54) | KDM4ESMN1; SMN2RECQLKMT2AALDH1A1 | |
| SCHEMBL2991769 | 0.75 | ALDH1A1 (0.64) | KDM4ESMN1; SMN2RECQLKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069341-B1 | PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS | GLAXO GROUP LTD (GB) | 2010-12-29 | — | — | EP | disclosed |
| US-20100035917-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| EP-2069341-A1 | PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS | Glaxo Group Limited (GB) | 2009-06-17 | — | — | EP | disclosed |
| US-20080176891-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| WO-2008034860-A1 | PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176891-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | KDM4E 1848/4885SMN1; SMN2 3855/4885RECQL 2757/4885 |
| US-20100035917-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS | PLK2, PDXK, MAP4K2 | KDM4E 594/4885SMN1; SMN2 3281/4885RECQL 2415/4885 |
| US-20080146606-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | KDM4E 1848/4885SMN1; SMN2 3855/4885RECQL 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.